India (~FY24/FY25 shape; check the current in IRDAI's Annual Report/Handbook). Non-life GDPI ≈ ₹2.9 lakh crore, growing in the low-to-mid teens, with penetration at ~1% of GDP. Health is the largest line at ~35 to 38%, then motor at ~30 to 32%, then fire, crop, marine, liability. On structure, start with the four listed-era PSU insurers (New India, Oriental, National, United). They're losing share with chronically weak underwriting, and New India's CR has run ~120% (illustrative). Then come the private multi-line leaders (ICICI Lombard, Bajaj Allianz GI, HDFC ERGO), the standalone health insurers known as "SAHIs" (Star Health, Care, Niva Bupa), and digital challengers such as Digit and Acko. India also has two supports of its own. One is "cash before cover": premium must be received before risk attaches, so there's no receivable risk on direct business. The other is GIC Re's dominance of domestic reinsurance.
Advertisement
How do motor and health insurance work in India?
- Motor splits in two. Own-damage (OD) is annually re-priced, brutally competitive and short-tail. Third-party (TP) is price-administered, compulsory and long-tail. Its rates are notified by the government with IRDAI's involvement, and they've been left unrevised for multi-year stretches (check the current schedule). Bodily-injury claims wind through Motor Accident Claims Tribunals for 3 to 8 years, with awards linked to wages that inflate. So TP is both the float generator, thanks to the long tail, and the place reserve risk concentrates, with wage inflation running on stale reserves at frozen prices. For any motor book, ask two questions. What's the OD/TP mix? And how prudent are the TP ultimates?
- Health is the growth engine, and it has a split personality. Retail health (individually sold, annually renewed, medically underwritten at entry, sticky) runs loss ratios of ~65 to 75% and is structurally the best large line in Indian GI: an annuity-like renewal book with pricing freedom. Medical inflation of ~10 to 14% does force regular re-pricing, though, and that fuels customer friction. Group health means corporate contracts bid annually, and it runs loss ratios near or over 100%. It's bought business, held for relationship reasons. It's also the classic way a GI company buys top-line growth that poisons the CR, so watch any insurer whose "health growth" is group-led. Government schemes such as the Ayushman Bharat tenders are thin-margin volume. Star Health's COVID year (FY22 CR ~117%; illustrative) shows the tail risk that even "short-tail" health carries. On the regulatory side, watch IRDAI's expenses-of-management caps (~30% of GWP for general insurers, 2023 regime), and its ongoing push on health-claims settlement practices.
- The ICICI Lombard profile (illustrative, ~FY24 scale; pull the actual disclosures): GDPI ~₹25,000 cr, CR ~103%, ROE ~17%, solvency ~2.5×, investment leverage ~4×. It's the textbook float case, a slightly-over-100 CR turned into a mid-teens ROE by a large, boring float. Your mini-project tests whether that equilibrium is durable.
How does the US P&C market differ?
United States. It's the world's deepest P&C market, and it's built differently. Pricing is free but regulated state by state (50 insurance commissioners, rate filings). There's no cash-before-cover. The tort system makes liability lines longer and nastier, which is what social inflation means. And catastrophe risk (hurricanes, wildfire) makes property a reinsurance-priced business. The post-2022 hard reinsurance market re-priced Florida homeowners and coastal property globally.
Personal auto is a duopoly-plus-fringe of discipline. Its two leaders are Progressive (the ~96 rule; 2024 CR in the high-80s on ~$74bn of net written premium; illustrative, check in the 10-K) and Berkshire's GEICO, which swung from CRs over 104 in the 2022 claims-inflation spike back to the low-90s by 2023–24 after aggressive re-pricing. In one-year lines, pricing power is repricing speed.
One warning. US health insurance (UnitedHealth, Elevance) is a different industry. It's managed care with ACA-mandated medical-loss-ratio floors of 80 to 85%, closer to a claims-processing utility on regulated spreads than to Indian retail health. Don't port Indian health-insurer intuitions onto it, or the other way round.
What carries over between the two markets?
Some things transfer between the markets: the combined-ratio-plus-float arithmetic, reserve honesty as the first quality screen, and the underwriting cycle. Others don't carry over. TP price administration is Indian. Cat/reinsurance dependence and social inflation are American. And health-line economics differ: a regulated utility in the US, a growth engine with mix risk in India.